Stocks were rising on Wednesday following the Federal Reserve’s decision to hold interest rates steady. The central bank ...
BofA notes press reports that the Trump administration is allegedly considering cutting HIV prevention activities from the CDC budget and that ...
The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...
We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...
Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...
Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health ...
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price ...
With cancer diagnoses and death rates in Michigan often higher than the national average, a new, patient-centered ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback